Julie J Miller1,2, Franziska Loebel3, Tareq A Juratli2,4, Shilpa S Tummala2,4, Erik A Williams5, Tracy T Batchelor1,6, Isabel Arrillaga-Romany1, Daniel P Cahill2,4. 1. Stephen E. and Catherine Pappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts. 2. Translational Neuro-Oncology Laboratory, Massachusetts General Hospital, Boston, Massachusetts. 3. Department of Neurosurgery, Charité University Hospital Berlin, Berlin, Germany. 4. Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts. 5. Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts. 6. Division of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.
Abstract
BACKGROUND: Isocitrate dehydrogenase (IDH) mutant gliomas are a distinct subtype, reflected in the World Health Organization (WHO) 2016 revised diagnostic criteria. To inform IDH-targeting trial design, we sought to characterize outcomes exclusively within IDH mutant gliomas. METHODS: We retrospectively analyzed 275 IDH mutant glioma patients treated at our institution. Progression was determined using low-grade glioma criteria from Response Assessment in Neuro-Oncology. We calculated survival statistics with the Kaplan-Meier method, and survival proportions were correlated with molecular, histologic, and clinical factors. RESULTS: During a median follow-up of 6.4 years, 44 deaths (7.6%) and 149 first progression (PFS1) events (54.1%) were observed. Median PFS1 was 5.7 years (95% CI: 4.7-6.4) and OS was 18.7 years (95% CI: 12.2 y-not reached). Consistent with prior studies, we observed an association of grade, molecular diagnosis, and treatment with PFS1. Following the first progressive episode, 79 second progression events occurred during a median follow-up period of 4.1 years. Median PFS following an initial progressive event (PFS2) was accelerated at 3.1 years (95% CI: 2.1-4.1). PFS2 was a surrogate prognostic marker, identifying patients with poorer overall survival. CONCLUSION: We report outcomes in a large cohort of IDH mutant glioma, providing a well-characterized historical control population for future clinical trial design. Notably, the interval between first and second recurrence (PFS2, 3.0 y) is shorter than time from diagnosis to first recurrence (PFS1, 5.7 y), evidence that these tumors clinically degenerate from an indolent course to an accelerated malignant phase. Thus, PFS2 represents a relevant outcome for trials investigating drug efficacy at recurrence.
BACKGROUND:Isocitrate dehydrogenase (IDH) mutant gliomas are a distinct subtype, reflected in the World Health Organization (WHO) 2016 revised diagnostic criteria. To inform IDH-targeting trial design, we sought to characterize outcomes exclusively within IDH mutant gliomas. METHODS: We retrospectively analyzed 275 IDH mutant gliomapatients treated at our institution. Progression was determined using low-grade glioma criteria from Response Assessment in Neuro-Oncology. We calculated survival statistics with the Kaplan-Meier method, and survival proportions were correlated with molecular, histologic, and clinical factors. RESULTS: During a median follow-up of 6.4 years, 44 deaths (7.6%) and 149 first progression (PFS1) events (54.1%) were observed. Median PFS1 was 5.7 years (95% CI: 4.7-6.4) and OS was 18.7 years (95% CI: 12.2 y-not reached). Consistent with prior studies, we observed an association of grade, molecular diagnosis, and treatment with PFS1. Following the first progressive episode, 79 second progression events occurred during a median follow-up period of 4.1 years. Median PFS following an initial progressive event (PFS2) was accelerated at 3.1 years (95% CI: 2.1-4.1). PFS2 was a surrogate prognostic marker, identifying patients with poorer overall survival. CONCLUSION: We report outcomes in a large cohort of IDH mutant glioma, providing a well-characterized historical control population for future clinical trial design. Notably, the interval between first and second recurrence (PFS2, 3.0 y) is shorter than time from diagnosis to first recurrence (PFS1, 5.7 y), evidence that these tumors clinically degenerate from an indolent course to an accelerated malignant phase. Thus, PFS2 represents a relevant outcome for trials investigating drug efficacy at recurrence.
Authors: David Capper; Hanswalter Zentgraf; Jörg Balss; Christian Hartmann; Andreas von Deimling Journal: Acta Neuropathol Date: 2009-10-02 Impact factor: 17.088
Authors: Robert B Jenkins; Hilary Blair; Karla V Ballman; Caterina Giannini; Robert M Arusell; Mark Law; Heather Flynn; Sandra Passe; Sara Felten; Paul D Brown; Edward G Shaw; Jan C Buckner Journal: Cancer Res Date: 2006-10-15 Impact factor: 12.701
Authors: M J van den Bent; D Afra; O de Witte; M Ben Hassel; S Schraub; K Hoang-Xuan; P-O Malmström; L Collette; M Piérart; R Mirimanoff; A B M F Karim Journal: Lancet Date: 2005 Sep 17-23 Impact factor: 79.321
Authors: Kathleen R Lamborn; W K Alfred Yung; Susan M Chang; Patrick Y Wen; Timothy F Cloughesy; Lisa M DeAngelis; H Ian Robins; Frank S Lieberman; Howard A Fine; Karen L Fink; Larry Junck; Lauren Abrey; Mark R Gilbert; Minesh Mehta; John G Kuhn; Kenneth D Aldape; Janelle Hibberts; Pamela M Peterson; Michael D Prados Journal: Neuro Oncol Date: 2008-03-04 Impact factor: 12.300
Authors: Edward G Shaw; Brian Berkey; Stephen W Coons; Dennis Bullard; David Brachman; Jan C Buckner; Keith J Stelzer; Geoffrey R Barger; Paul D Brown; Mark R Gilbert; Minesh Mehta Journal: J Neurosurg Date: 2008-11 Impact factor: 5.115
Authors: D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler Journal: Science Date: 2008-09-04 Impact factor: 47.728
Authors: Christian Hartmann; Jochen Meyer; Jörg Balss; David Capper; Wolf Mueller; Arne Christians; Jörg Felsberg; Marietta Wolter; Christian Mawrin; Wolfgang Wick; Michael Weller; Christel Herold-Mende; Andreas Unterberg; Judith W M Jeuken; Peter Wesseling; Guido Reifenberger; Andreas von Deimling Journal: Acta Neuropathol Date: 2009-06-25 Impact factor: 17.088
Authors: Koichi Ichimura; Danita M Pearson; Sylvia Kocialkowski; L Magnus Bäcklund; Raymond Chan; David T W Jones; V Peter Collins Journal: Neuro Oncol Date: 2009-05-12 Impact factor: 12.300
Authors: Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner Journal: N Engl J Med Date: 2009-02-19 Impact factor: 176.079
Authors: Esraa Mohamed; Anupam Kumar; Yalan Zhang; Albert S Wang; Katharine Chen; Yunita Lim; Anny Shai; Jennie W Taylor; Jennifer Clarke; Stephanie Hilz; Mitchel S Berger; David A Solomon; Joseph F Costello; Annette M Molinaro; Joanna J Phillips Journal: Neuro Oncol Date: 2022-09-01 Impact factor: 13.029
Authors: Jing Wu; Ying Yuan; Debra A Long Priel; Danielle Fink; Cody J Peer; Tristan M Sissung; Yu-Ting Su; Ying Pang; Guangyang Yu; Madison K Butler; Tito R Mendoza; Elizabeth Vera; Salman Ahmad; Christine Bryla; Matthew Lindsley; Ewa Grajkowska; Kelly Mentges; Lisa Boris; Ramya Antony; Nancy Garren; Christine Siegel; Nicole Lollo; Christine Cordova; Orwa Aboud; Brett J Theeler; Eric M Burton; Marta Penas-Prado; Heather Leeper; Javier Gonzales; Terri S Armstrong; Katherine R Calvo; William D Figg; Douglas B Kuhns; John I Gallin; Mark R Gilbert Journal: Clin Cancer Res Date: 2021-03-30 Impact factor: 13.801
Authors: Joachim P Steinbach; Patrick N Harter; Oliver Bähr; Eike Steidl; Katharina Filipski; Pia S Zeiner; Marlies Wagner; Emmanouil Fokas; Marie-Therese Forster; Michael W Ronellenfitsch; Iris Divé Journal: J Cancer Res Clin Oncol Date: 2021-02-04 Impact factor: 4.553